Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine

Cancer Gene Therapy volume 13, pages 592–597 (2006)Cite this article

Abstract

Human papillomavirus (HPV) is the etiologic agent for cervical cancer. In Mexico, a women dies every 2 h, and since 1990 the statistics have shown that the numbers of deaths are increasing. We conducted a phase II clinical trial to evaluate the potential use of the MVA E2 recombinant vaccinia virus in treating high-grade lesions (CIN 2 and CIN 3) associated with oncogenic papillomavirus. Fifty-four female patients with high degree lesions were treated either with an MVA E2 therapeutic vaccine or with conization. Thirty-four women received the therapeutic vaccine, at a total of 107 virus particles per dose injected directly into the uterus once every week over a 6-week period. Twenty control patients were treated with conization. By colposcopy, 19 patients out of 34 showed no lesion, in three patients the lesions were reduced by 85–90%, in eight other lesions had reduced by 60%, and in four more patients, they were reduced by 25%. Histological analysis showed total elimination of high-grade lesions in 20 out of 34 patients after treatment with MVA E2. Eleven patients had a 50% reduction in lesion size. In two other patients, the lesion was reduced to CIN 2 and in one more patient the lesion was reduced to low grade (CIN 1). All patients developed antibodies against the MVA E2 vaccine, and generated a specific cytotoxic response against papilloma-transformed cells. DNA viral load was significantly reduced in MVA E2-treated patients. Conization eliminated the lesions in 80% of the patients, but patients did not develop cytotoxic activity specific against cancer cells and did not eliminate the papillomavirus. In addition, three patients treated with conization had recurrence of lesions 1 year later. These results show that therapeutic vaccination with MVA E2 proved to be very effective in stimulating the immune system against papillomavirus, and in generating regression of high-grade lesion.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Jansen K, Shaw A . Human papillomavirus vaccines and prevention of cervical cancer. Ann Rev Med 2004; 55: 319–331.

    Article  CAS  Google Scholar 

  2. Parkin DM, Laara E, Muir CS . Estimates of the world-wide frequency of sixteen major cancers in 1980. Int J Cancer 1980; 41: 184–197.

    Article  Google Scholar 

  3. Rosales C, Valadez G, Arrellin R, Merchant H, Rosales R . A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother 2000; 49: 347–360.

    Article  CAS  Google Scholar 

  4. Valadez V, Sutter G, Jose M, Garcia-Carranca A, Erfle V, Moreno M et al. Human tumor growth is inhibited by vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer 2000; 88: 1650.

    Article  Google Scholar 

  5. Corona-Gutiérrez C, Tinoco A, Contreras M, Navarro T, Calzado P, Vargas L et al. A phase II study. Efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther 2002; 13: 1127–1140.

    Article  Google Scholar 

  6. Corona-Gutiérrez C, Tinoco A, Navarro T, López-Contreras M, Risco-Cortes R, Calzado P et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2 and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15: 421–431.

    Article  Google Scholar 

  7. Binns MM, Smith GL . Recombinant Poxvirus. ACR Press: Boca Raton, Florida, 1993.

    Google Scholar 

  8. Sutter G, Wyatt LS, Foley PL, Bennick JR, Moss B . A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994; 12: 53–59.

    Article  Google Scholar 

  9. Roque-Reséndiz J, Rosales R, Herion P . MVA ROP 2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis. Parasitology 2004; 128: 397–405.

    Article  Google Scholar 

  10. Hanke T, McMichael A, Mwau M, Wee EG, Ceberej I, Patel S et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 2002; 20: 1995–1998.

    Article  CAS  Google Scholar 

  11. Wyatt L, Whitehead S, Venanzi K, Murphy B, Moss B . Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 1999; 18: 392–397.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital de Gineco Obstetricia, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico

    E García-Hernández, J L González-Sánchez & A Andrade-Manzano

  2. FES Zaragoza, National Autonomous University of México, Mexico City, Mexico

    M L Contreras

  3. Hospital de la Mujer, Jacona, Zamora Michoacan, Mexico City, Mexico

    S Padilla

  4. Jefatura de Prestaciones Médicas, IMSS, Mexico City, Mexico

    C C Guzmán

  5. Lemery, S.A de C.V, Mexico City, Mexico

    R Jiménez, L Reyes, G Morosoli & M L Verde

  6. Department of Biotechnology and Molecular Biology, Instituto de Investigaciones Biomedicas, National Autonomous University of México, Mexico City, Mexico

    R Rosales

Authors
  1. E García-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J L González-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Andrade-Manzano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M L Contreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Padilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C C Guzmán
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Reyes
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Morosoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M L Verde
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R Rosales
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Rosales.

Rights and permissions

Reprints and permissions

About this article

Cite this article

García-Hernández, E., González-Sánchez, J., Andrade-Manzano, A. et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13, 592–597 (2006). https://doi.org/10.1038/sj.cgt.7700937

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700937

Keywords

This article is cited by

Search

Advanced search

Quick links